Provided by Tiger Trade Technology Pte. Ltd.

HORIZON KINETICS MEDICAL ETF

34.66
-0.1046-0.30%
Post-market: 34.760.1046+0.30%16:10 EDT
Volume:188
Turnover:7K
Market Cap:16.29M
PE:- -
High:34.66
Open:34.76
Low:34.66
Close:34.76
52wk High:37.90
52wk Low:30.79
Shares:469.95K
Float Shares:469.95K
Volume Ratio:0.58
T/O Rate:0.04%
Dividend:0.41
Dividend Rate:1.18%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Abbvie and Iambic Announce Collaboration to Accelerate AI-Driven Drug Discovery

THOMSON REUTERS
·
Sep 21

Abbvie - Iambic to Receive Upfront Payment, Milestone Payments, and Tiered Royalties from Collaboration

THOMSON REUTERS
·
Sep 21

Abbvie - Partnership to Accelerate Small Molecule Drug Discovery in Immunology, Neuroscience, Oncology

THOMSON REUTERS
·
Sep 21

J&J - Caplyta Demonstrates Statistically Significant Rapid Reduction in Manic Symptoms at Week 3

THOMSON REUTERS
·
Sep 21

Caplyta® (Lumateperone) Shows Significant and Rapid Improvement in Bipolar Mania in Pivotal Phase 3 Study

THOMSON REUTERS
·
Sep 21

J&J - Caplyta Well-Tolerated; Dry Mouth and Nausea Most Common Adverse Events

THOMSON REUTERS
·
Sep 21

Adarx Pharmaceuticals: IPO Price Expected Between $15 and $17 Per Share

Reuters
·
Sep 21

U.S. Stocks on the MOVE-Accenture, Arhaus, Alkermes

Reuters
·
Sep 21

Alkermes jumps 8% to $46.99 after Phase I adult ADHD data

TIPRANKS
·
Sep 21

Oura Files for Initial Public Offering on Nasdaq

MT Newswires Live
·
Sep 21

Regulator Aims to Establish 30 National Quality Inspection Centers Under the 15th Five-Year Plan

Deep News
·
Sep 21

LIVE Markets-Big Beauty Faces Growing Threat from AI, Smaller Rivals

Reuters
·
Sep 21

ADARx Pharmaceuticals to Sell 21.9 Million Shares at $15-$17 Each in IPO

Dow Jones
·
Sep 21

Drug Innovation and Property Sectors Rally Together! Hong Kong Stock Connect Innovation Drug ETF's Underlying Index Spikes Up to 6.15% Intraday! Real Estate Surges for a Second Straight Day, Vanke A and Greenland Holdings Notch Consecutive Limit-Ups!

Deep News
·
Sep 21

Smart Ring Maker Oura Eyes $15.6 Billion IPO Valuation in Fall Listings Demand Test

Reuters
·
Sep 21

Alkermes Shares Rise 6.5% Premarket After Positive Results from Early-Stage Study of Adhd Drug

THOMSON REUTERS
·
Sep 21

Alkermes announces Phase 1b results of ALKS 7290 in ADHD

TIPRANKS
·
Sep 21

Alkermes Reports Positive Phase 1b Proof-of-Concept Data for ALKS 7290 in Adult ADHD

Reuters
·
Sep 21

Alkermes -Alks 7290 Generally Well Tolerated at All Doses in Healthy Volunteers and Adults with Adhd

THOMSON REUTERS
·
Sep 21

Alkermes Announces Positive Phase 1B Results Demonstrating Clinical Proof-of-Concept for Alks 7290 in Adults with Attention-Deficit Hyperactivity Disorder (Adhd)

THOMSON REUTERS
·
Sep 21